ENVASARC: A pivotal trial of envafolimab, and envafolimab in combination with ipilimumab, in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.

Sandra P. DAngelo,Steven I. Robinson,Joelle Lam,Bonne J. Adams,James L. Freddo,Charles P. Theuer,Robert G. Maki

ENVASARC: A pivotal trial of envafolimab, and envafolimab in combination with ipilimumab, in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.

2021

Sandra P. DAngelo
Steven I. Robinson
Joelle Lam
Bonne J. Adams
James L. Freddo
Charles P. Theuer
Robert G. Maki

TPS11581Background: Metastatic undifferentiated Pleomorphic Sarcoma (UPS) and the genetically related myxofibrosarcoma (MFS) are soft tissue sarcoma (STS) subtypes with poor prognoses. While respon...

Keywords:

Myxofibrosarcoma
Medicine
Soft tissue sarcoma
Ipilimumab
Metastatic Undifferentiated Pleomorphic Sarcoma
Chemotherapy
in patient
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations